Hanmi's Innovative Collaboration with Gilead
Hanmi Pharm and Health Hope Pharma (HHP) have taken a significant step in the pharmaceutical landscape by partnering with Gilead Sciences, Inc. This collaboration involves granting Gilead an exclusive license to Encequidar, showcasing Hanmi's innovative Orascovery™ oral drug delivery platform.
What is Orascovery™?
Orascovery™ is an advanced proprietary platform developed by Hanmi that converts injectable medicines into more convenient oral formulations. This technology positions Hanmi at the forefront of drug delivery innovation, particularly evident in their development of Encequidar, a first-in-class P-gp inhibitor.
Details of the Agreement
Under the terms of this collaboration, Gilead is granted exclusive global rights to develop and commercialize Encequidar specifically in the field of virology. Alongside licensing rights, Hanmi and HHP will provide drug supply, share invaluable technical expertise, and engage as essential project partners. This partnership is built on a foundation of trust, with both Hanmi and HHP poised to receive initial payments, ongoing development funding, and royalties from successful net sales.
Statements from Key Figures
Dr. Dennis Lam, the founder of HHP, expressed enthusiasm in their announcement regarding the agreement with Gilead and Hanmi. He emphasized the significance of Encequidar in creating innovative oral formulations across various medical fields, highlighting a promising future for both the Hong Kong biotech industry and HHP. Dr. Lam’s vision for the company's pipeline, especially Oraxol, underscores their commitment to advancing healthcare solutions.
Jae-Hyun Park, CEO of Hanmi Pharm, echoed similar sentiments by recognizing the agreement as a testament to Hanmi's R&D prowess and its transformative potential. The collaboration opens doors for strategic partnerships aimed at furthering innovation, demonstrating Hanmi's dedication to enhancing patient access in global markets.
The Evolution of Encequidar
Encequidar's journey began with Hanmi's partnership with Athenex, where it was initially out-licensed alongside the oral anticancer drug Oraxol in 2011. Following Athenex's restructuring, the rights transitioned to Health Hope Pharma, who is currently progressing through clinical trials for Oraxol in various regions including the U.S. and Hong Kong, with future expansion plans that encompass Europe and Asia.
Future Directions and Potential Impact
This collaboration could pave the way for innovative developments in oral drug formulations, enhancing the overall patient experience and accessibility to new treatments. Hanmi’s continued exploration of strategic partnerships will play a crucial role in accelerating innovations that promise to reach patients worldwide.
Frequently Asked Questions
What is the significance of Hanmi's collaboration with Gilead?
This collaboration highlights Hanmi's innovative drug delivery technology and the potential for developing new oral formulations.
What is the Orascovery™ platform?
Orascovery™ is a proprietary platform that allows the conversion of injectable medicines into oral formulations, enhancing drug accessibility.
Who is involved in the agreement besides Gilead?
The agreement also involves Health Hope Pharma (HHP), which plays a critical role in drug supply and technical expertise.
What are the key benefits of the licensing agreement?
The agreement offers financial benefits through upfront payments and royalties, alongside shared knowledge in drug development.
How does this collaboration affect the future of drug delivery?
The collaboration is expected to accelerate innovations in oral drug formulations, improving patient access and treatment options.
